

SPECIALTY GUIDELINE MANAGEMENT

ODOMZO (sonidegib)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

Compendial Uses

Nodal or distant metastatic basal cell carcinoma

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Basal Cell Carcinoma

Authorization of 12 months may be granted for treatment of locally advanced or metastatic basal cell carcinoma.

III. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continuation of therapy for an indication outlined in Section II when there is no evidence of unacceptable toxicity or disease progression on the current regimen.

IV. REFERENCES

1. Odomzo [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2017.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at <http://www.nccn.org>. Accessed November 09, 2018.